New Molecular Target for Treating Type 2 Diabetes Identified
Oct 20, 2026
Researchers identified Miro1 as a regulator of skeletal muscle insulin resistance, opening the possibility of diabetes treatments that address a molecular mechanism underlying impaired glucose…
Read MoreBlood Test Identifies Residual Cancer
Oct 21, 2026Preventive Cancer Vaccine Maker Nouscom Raises $135M and Presents Promising Lynch Syndrome Data
Oct 21, 2026Rare Structural Mutations in NSCLC Successfully Targeted
Oct 21, 2026Some Assistive Reproductive Technology May Raise Childhood Cancer Risk
Oct 21, 2026New PET Imaging Changes Care in Clear Cell Kidney Cancer
Oct 21, 2026Hussam Al Kateb: Inside Mayo Clinic’s Molecular Diagnostic Revolution
Oct 21, 2026Long QT Syndrome Risk Clarified by Functional Map of KCNQ1 Gene Variants
Oct 21, 2026
Digital Twins Identify Drug Combination to Prevent Preterm Birth
Oct 21, 2026
With In Vivo ‘Gene Writers,’ Tessera Shows DNA Engineering Differentiation
Oct 21, 2026
Radiology’s New Frontier Is the Workflow
Oct 20, 2026
Beyond Detection: Rethinking Radiology in the Age of AI
Oct 20, 2026
Can AI Agents Help the Right Patients Find the Right Trials?
Oct 20, 2026
News & Features
Gene-Edited CAR T Expands Rare Disease Horizons
August 01, 2026Combining CAR T with CRISPR or TALEN is enabling more precise, scalable cell therapies for autoimmune, fibrotic, and genetic disorders.
From Mila to Many: Making Ultra-Rare Disease Therapies More Accessible
August 01, 2026Newer options like the therapies being developed by Forster and colleagues at Nerai Biosciences, alongside others like potentially curative gene therapies, are on the horizon…
Drug Repurposing’s Next Challenge: Turning Discoveries Into Treatments
August 01, 2026The U.S. Food and Drug Administration (FDA) is now actively involving patients, researchers, and clinicians in efforts to prioritize drug repurposing in areas where commercial…
Highly Multiplexed Droplet Digital PCR for Ultra-Sensitive NSCLC Biomarker Detection in Research Workflows
In this IPM webinar, two experts will discuss the growing role of ddPCR in clinical research and translational oncology.
Surbhi Jain, PhD, MBBS
Staff Scientist
Bio-Rad Laboratories
Prithwish Pal, PhD
Director, Global Product Marketing – Oncology
Bio-Rad Laboratories
Early Drivers of Autoimmune Kidney Damage Identified, Opening Door to Targeted Treatment
Oct 19, 2026Researchers uncovered how injured kidney cells recruit immune cells that worsen inflammation and demonstrated an experimental antibody strategy that reduced kidney damage in mice.
Molecular Profiling May Predict Deep Response to Multiple Myeloma Treatment
Oct 19, 2026A new study suggests that the molecular characteristics of multiple myeloma tumors could help predict which patients achieve deep responses to four-drug therapy, offering a…
IMU Biosciences and UK Biobank to Create Large Immune Dataset
Oct 19, 2026IMU Biosciences will help create a large and detailed immune dataset for 80,000 people in the UK Biobank with help from Waters Corporation and Ultima…
Podcast Series
Behind the Breakthroughs
Join host Jonathan D. Grinstein, PhD, North American Editor for Inside Precision Medicine, as he uncovers the stories behind the pioneers driving the precision medicine revolution.
Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter.
